Drugs that contain Siponimod Fumaric Acid

1. Drug name - MAYZENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
May, 2024

(1 year, 7 months from now)

CN1787817B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1787817A NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN102174042B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN102174042A NOVARTIS Immunosuppressant Compound And Composition
Jul, 2015

(7 years ago)

CN1791592A NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1791592B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1816544B NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1816544A NOVARTIS Immunosuppressant Compounds And Compositions
Jul, 2015

(7 years ago)

CN1791395A NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

CN1791395B NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

IN234287B NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

IN200503060P4 NOVARTIS Immunosuppresant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336A2 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551A2 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP2514743A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP2514743B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist Nov, 2030

(8 years from now)

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription
EQ 2MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.